Advertisement
Screener

Krispy Kreme, Inc. (DNUT) Spending and interest coverage

Krispy Kreme, Inc. (DNUT) Spending and interest coverage

  • R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-28..
  • Stock-based compensation / revenue · 12 months: Value 0.92%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-28..
  • Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..

Spending and interest coverage

Overview →

Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
R&D / revenue · 12 months(m)Research and development expense / revenue. Period ending 2026-06-28.

Calculation unavailable: missing inputs remain (m).

Stock-based compensation / revenue · 12 months0.92%Share-based compensation / revenue. Period ending 2026-06-28.

$13.55M ÷ $1.47B × 100 ≈ 0.92%

Interest coverage · 12 months(m)Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Research and development spending(m)
Revenue1.47B USDRevenue from Contract with Customer, Excluding Assessed Tax
Stock-based compensation13.55M USDShare-based Payment Arrangement, Noncash Expense
Operating income-29.05M USDOperating Income (Loss)
Interest expense · reported / estimated(m) · Estimated expense assumptions

Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingResearch and development spending (USD)Revenue (USD)Stock-based compensation (USD)Operating income (USD)Interest expense · reported / estimated (USD)R&D / revenueSBC / revenueInterest coverageInterest expense basis
2026-06-28(m)$1.47B$13.55M$-29.05M(m)(m)0.92%(m)(m)
2026-03-29(m)$1.51B$14.90M$-452.63M(m)(m)0.98%(m)(m)
2025-12-28(m)$1.52B$12.87M$-469.27M(m)(m)0.84%(m)(m)
2025-09-28(m)$1.53B$18.56M$-473.50M(m)(m)1.21%(m)(m)
2025-06-29(m)$1.54B$27.75M$-482.32M(m)(m)1.80%(m)(m)
2025-03-30(m)$1.60B$30.77M$-40.91M(m)(m)1.93%(m)(m)
2024-12-29(m)$1.67B$35.15M$-8.73M(m)(m)2.11%(m)(m)
2024-09-29(m)$1.71B$30.98M$-2.57M(m)(m)1.81%(m)(m)
2024-06-30(m)$1.74B$28.46M$11.32M(m)(m)1.64%(m)(m)
2024-03-31(m)$1.71B$25.64M$10.11M(m)(m)1.50%(m)(m)
2023-12-31(m)$1.69B$24.20M$13.14M(m)(m)1.44%(m)(m)
2023-10-01(m)$1.64B$22.67M$23.69M(m)(m)1.38%(m)(m)
2023-07-02(m)$1.61B$18.05M$24.77M(m)(m)1.12%(m)(m)
2023-04-02(m)$1.58B$18.67M$26.64M(m)(m)1.18%(m)(m)
2023-01-01(m)$1.53B$18.17M$28.98M(m)(m)1.19%(m)(m)
2022-10-02(m)$1.50B$19.27M$40.24M(m)(m)1.29%(m)(m)
2022-07-03(m)$1.46B$22.76M$43.09M(m)(m)1.56%(m)(m)
2022-04-03(m)$1.44B$25.60M$44.71M(m)(m)1.78%(m)(m)
2022-01-02(m)$1.38B$22.92M$41.10M(m)(m)1.66%(m)(m)
2021-10-03(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-07-04(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-04-04(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-01-03(m)$1.12B$11.60M$4.28M(m)(m)1.03%(m)(m)
2020-09-27(m)(m)(m)(m)(m)(m)(m)(m)(m)
2020-06-28(m)(m)(m)(m)(m)(m)(m)(m)(m)
2019-12-29(m)$959.41M$10.74M$38.00M(m)(m)1.12%(m)(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.